Proactive Investors - Run By Investors For Investors

CannPal Animal Therapeutics teams up with University of Melbourne

A cooperative relationship in the field of veterinary science will be established.
two hands shaking with letter MOU in background
The aim is to complete a pilot study targeting epilepsy in dogs in 2019

CannPal Animal Therapeutics Ltd (ASX:CP1) has entered into a memorandum of understanding (MoU) with the University of Melbourne to research an epilepsy treatment for dogs.

Under the MoU, both parties will work on terms to establish a cooperative relationship in the field of veterinary science to complete a pilot study to determine the efficacy of cannabidiol (CBD) treatment for epilepsy in dogs in 2019.

The MoU builds on CannPal’s current research pipeline which includes the phase Ib study for CPAT-01, a pain control in dogs, and its extension CPAT-01C for cats.

READ:  CannPal Animal Therapeutics receives approval to advance clinical studies

CannPal's managing director Layton Mills said: “This MoU with the University of Melbourne is the latest in a long line of strategic agreements CannPal has entered, to establish the company as a global leader in cannabinoid-derived therapeutics for companion animals.

“It’s further validation of the high-quality research we are undertaking and we look forward to working with the University on this project.”

Cannabidiol has a number of reported health benefits

Cannabidiol is a non-psychoactive compound derived from cannabis with a number of reported health benefits which include anxiolytic, anti-inflammatory, antibacterial and antiseizure properties.

In June 2018, the US Food and Drug Administration (FDA) approved Epidiolex (cannabidiol) oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy in human patients of 2 years of age and older.

This is the first FDA-approved drug that contains a purified drug substance derived from marijuana and the Company is hopeful that similar effects using cannabinoids can be seen in dogs with idiopathic epilepsy.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CP1 profile View Profile

CannPal Animal Therapeutics Ltd Timeline

Related Articles

cannabis bud on tray
April 25 2019
Armed with a new partnership with Canada's largest pharmacy and an international cultivator, Flowr is aiming to provide medicinal and recreational consumers around the world with premium, high-quality cannabis
cannabis leaf next to bottle
April 29 2019
The cannabis holding company has four unique, synergistic business under its umbrella
FSD Pharma facility
June 11 2019
The indoor hydroponic facility will be optimized for large-scale, medical-grade cannabis production and once complete, is expected to have over 3.9 million sq/ft available for production

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use